Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 3/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.33 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11443850 | 0.86 | HAO1 (0.46) | HAO1ASIC3MAP3K14EGFRMAPT | |
| SCHEMBL15107028 | 0.85 | GRM5 (0.44) | GRM5HAO1ALDH1A1MAPK1PTGES2 | |
| SCHEMBL11443958 | 0.83 | MAPT (0.43) | GRM5MAP3K14ALDH1A1MAPK1MAPT | |
| SCHEMBL11549060 | 0.82 | ASIC3 (0.42) | ASIC3MAP3K14ALDH1A1PTGES2MAPT | |
| SCHEMBL2811570 | 0.79 | GRM5 (0.44) | GRM5HAO1ASIC3MAP3K14EGFR | |
| SCHEMBL2629434 | 0.79 | GRM5 (0.49) | GRM5HAO1ASIC3MAP3K14EGFR | |
| SCHEMBL238140 | 0.78 | GRM5 (0.38) | GRM5ALDH1A1MAPK1MAPTMEN1 | |
| SCHEMBL11548721 | 0.78 | HAO1 (0.43) | HAO1ASIC3ALDH1A1PTGES2MAPT | |
| SCHEMBL24506081 | 0.78 | HAO1 (0.41) | HAO1ASIC3MAP3K14EGFRMAPT | |
| SCHEMBL1477501 | 0.78 | KCNH2 (0.50) | GRM5HAO1ASIC3MAP3K14EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4223172-A | DEHYDROGENATION HALOGENATIVE WITH PALLADIUM-PHOSPHINE COMPLEX CATALYST | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1980-09-16 | — | — | US | claimed |
| WO-2024033280-A1 | FUROPYRIDIN AND FUROPYRIMIDIN, INHIBITORS OF PI4K, FOR USE IN THE TREATMENT OF PARASITE INFECTION AND MALARIA | MERCK PATENT GMBH (DE) | 2024-02-15 | — | — | WO | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-4223172-A | DEHYDROGENATION HALOGENATIVE WITH PALLADIUM-PHOSPHINE COMPLEX CATALYST | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1980-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | GRM5 456/4885HAO1 968/4885ASIC3 4324/4885 |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | GRM5 1882/4885HAO1 762/4885ASIC3 4386/4885 |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | GRM5 1882/4885HAO1 762/4885ASIC3 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.